Clarity Pharmaceuticals Ltd has released a press release.
$11.1 million RDTI and refocus on high-priority programs
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- SECuRE trial update: First patient treated in the Phase II Cohort Expansion
- First patient treated in the Phase II of the SECuRE trial
- SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.
- Clarity signs Cu-64 Supply Agreement with UQ
- Appendix 4D
Later from Clarity Pharmaceuticals
- Clarity signs commercial-scale copper-64 Supply Agreement
- Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano
- AMPLIFY trial commences
- Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences
- First patient imaged in Phase III AMPLIFY trial
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals